- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Dolutegravir + rilpivirine – July 2018
Dolutegravir + rilpivirine: Tablet containing dolutegravir 50 mg with rilpivirine 25 mg; Juluca®
Last updated
26 October 2018